Furmonertinib
- Generic Name
- Furmonertinib
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
用于既往经表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI)治疗时或治疗后出现疾病进展，并且经检测确认存在EGFR T790M突变阳性的局部晚期或转移性非小细胞性肺癌(NSCLC)成人患者的治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-05
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 144
- Registration Number
- NCT06674343
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Evaluating High-dose Furmonertinib With Bevacizumab and Pemetrexed for EGFRm NSCLC With Leptomeningeal Metastasis
Not Applicable
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT06643000
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Furmonertinib Combined With Anlotinib in Lung Adenocarcinoma Patients With EGFR Mutations and Brain Metastases
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2024-07-03
- Target Recruit Count
- 27
- Registration Number
- NCT06483672
High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Changhai Hospital
- Target Recruit Count
- 84
- Registration Number
- NCT06394674
- Locations
- 🇨🇳
Changhai Hospital, Shanghai, China
An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-08
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- Tang-Du Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06352502
- Locations
- 🇨🇳
Tangdu Hopspital, Xi'an, Shanxi, China
A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis
- First Posted Date
- 2024-04-01
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- Jiangsu Province Nanjing Brain Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06339242
- Locations
- 🇨🇳
Nanjing Brain Hospital, Nanjing, Jiangsu, China
High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-03-20
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Taizhou Hospital
- Target Recruit Count
- 255
- Registration Number
- NCT06319950
To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Juan LI, MD
- Target Recruit Count
- 20
- Registration Number
- NCT06192849
- Locations
- 🇨🇳
Sichuan cancer hospital, Chengdu, Sichuan, China
The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- Target Recruit Count
- 30
- Registration Number
- NCT06117644
IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- InxMed (Shanghai) Co., Ltd.
- Target Recruit Count
- 110
- Registration Number
- NCT05994131
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath